ArticleAmerican journal of translational research2026
Effects of high-dose intravenous immunoglobulin on efficacy, inflammatory markers, and pulmonary function in adults with severe acute viral pneumonia.
Article in American journal of translational research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo elucidate the effects of high-dose intravenous immunoglobulin (HD-IVIG) therapy on inflammatory markers, and pulmonary function (PF) in adult patients with severe acute viral pneumonia (SAVP).
methodsA total of 178 adult patients with SAVP were selected and divided into two groups according to their actual treatment regimens. Eighty-eight patients receiving routine treatment were assigned to the control group, and 90 patients receiving HD-IVIG were assigned to the observation group. Clinical efficacy, symptom relief time, inflammatory markers, PF, humoral immunity, and quality of life (SF-36) were compared across multiple dimensions. Factors influencing treatment ineffectiveness in adult patients with SAVP were also investigated.
resultsThe overall clinical efficacy in the observation group was significantly better than that in the control group, with a significantly shorter symptom relief time. Compared with routine treatment, HD-IVIG therapy significantly reduced the levels of C-reactive protein (CRP) and procalcitonin (PCT) while substantially elevating the levels of interleukin (IL)-2, various PF indicators, humoral immunity markers, and scores on all dimensions of the SF-36. Age, coronary heart disease, CRP levels, and treatment modality are associated factors increasing the risk of treatment ineffectiveness in adult SEVP patients.
conclusionHD-IVIG therapy has a definite clinical efficacy in treating adult patients with SAVP.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.